I am a health economist working within pharmaceutical industry. I am dedicated to bring innovative medicine to patients. The most of European countries have scare healthcare resources which should be distributed in a cost effective way, meaning most value for every money. For this purpose the new drugs are in several countries required to provide the evidence for the cost effectiveness. But the tools and models used for this type of evaluations do not fit for rare disease or therapeutic areas with small patient populations.
Invited by: Ирина Люта
if the data has not been changed, no new rows will appear.
Day | Followers | Gain | % Gain |
---|---|---|---|
December 03, 2023 | 15 | +1 | +7.2% |
June 02, 2022 | 14 | -1 | -6.7% |
March 18, 2022 | 15 | +3 | +25.0% |
November 04, 2021 | 12 | -2 | -14.3% |
September 28, 2021 | 14 | +4 | +40.0% |